Christopher Eden attended Guy’s Hospital Medical School and King’s College School for Medicine and Dentistry, achieving an MBBS in 1985 from the University of London after winning both the Surgery and Paediatric Prizes. He became a Fellow of the Royal College of Surgeons in 1995 and achieved a Master of Surgery degree from the University of London in 1997.
As a surgical trainee he became a pioneer of laparoscopy urological surgery, having performed the UK’s first laparoscopic pyeloplasty in 1994, first laparoscopic radical prostatectomy in 2000 and first laparoscopic radical cystectomy in 2001. He has one of the world’s largest personal series of major laparoscopic urological procedures at over 2,500 cases and has published more than 50 peer-reviewed papers on laparoscopic urology, 9 book chapters and a book.
His training in laparoscopic kidney and prostate surgery included working with experts at the Institute Mutualiste Montsouris, in Paris, France at John Hopkins Hospital, Baltimore and at The Cleveland Clinic, Cleveland, USA, thanks to a Travelling Fellowship from the Ethicon Foundation Fund.
He was awarded the Independent Healthcare Award winner for Medical Practice in 2007 and was described in a poll of 40 UK Consultant Urologists published in the national Daily Mail newspaper as 'probably the leader in the field of keyhole radical prostatectomy.'
He is a reviewer for The British Journal of Urology International, Urology, European Urology, The Journal of Urology, The Scandanavian Journal of Urology and Nephrology and Urology professional journals and was voted as reviewer of the month for European Urology in April 2010.
He is Specialist advisor to the UK’s National Institute for Clinical Health and Excellence, a member of Editorial Board for European Urology and a member of the International Laparoscopy Prostate Cancer Working Group.
He has operated, lectured and instructed on laparoscopic urology in Europe, Africa, America, Asia and Australasia. His current clinical research interests include surgery for high-risk prostate cancer and extended pelvic lymphadenectomy for intermediate-risk prostate cancer.